Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells

https://doi.org/10.1016/S0165-2478(98)00025-XGet rights and content
Under a Creative Commons license
open archive

Abstract

Angiotensin converting enzyme (ACE) inhibitors have immunomodulatory functions and can suppress a number of proinflammatory, monocyte/macrophage-derived cytokines. Interleukin-12 is a cytokine produced primarily by monocytes and macrophages, which plays an essential role in cell mediated immunity and stimulates the development of T helper type 1 immune responses. In this study, we investigated the ability of ACE inhibitors, captopril and lisinopril, to suppress IL-12 production by human peripheral blood mononuclear cells (PBMC). We show that both ACE inhibitors significantly inhibit production of IL-12 by PBMC stimulated with bacterial lipopolysaccharide (LPS) or Staphylococcus aureus Cowan (SAC). Although both ACE inhibitors also suppressed IFN-γ production by human anti-CD3/anti-CD28-stimulated T-cells, the addition of exogenous IFN-γ to the PBMC stimulation medium does not abrogate the ability of ACE inhibitors to suppress IL-12 production. Inhibition of IL-12 was not associated with inhibition of IL-1β, but correlated with the suppression of ACE. Therefore, suppression of IL-12 may contribute to the immunomodulatory effect of ACE inhibitors and may be responsible for the beneficial effect of captopril and other ACE inhibitors in inflammatory or autoimmune conditions in which IL-12 is involved.

Keywords

Angiotensin converting enzyme inhibitor
Captopril
Interleukin-12
Lisinopril
Peripheral blood mononuclear cells

Cited by (0)